Purpose : AHSA1 is an activator Of HSP90 ATPase, which is a biomarker associated with oncogenesis in pan-cancer. The significance of AHSA1 in EGFR mutated lung adenocarcinoma(LUAD) remains uncertain. The purpose of th...
详细信息
Purpose : AHSA1 is an activator Of HSP90 ATPase, which is a biomarker associated with oncogenesis in pan-cancer. The significance of AHSA1 in EGFR mutated lung adenocarcinoma(LUAD) remains uncertain. The purpose of the research is to uncover the function of AHSA1 in EGFR mutated lung *** and Methods:In EGFR mutated LUAD tissues, the examination of AHSA1 and other gene expressions was carried out using tissue microarrays. Date from TCGA-LUAD were employed to explore AHSA1's expression, potential regulatory pathways, and prognostic significance. The protein expression of AHSA1 and other gene products was evaluated using Western blotting(WB) or flow cytometry. Stable overexpression or knock-down of AHSA1 was achieved through lentivirus. Following that, employing EdU, Annexin V/PI staining, Caspase 3/7staining, TMRM staining, Fluo4-AM staining, and Transwell assay and Xenograft models, in vitro experiments and in vivo expreiments were performed to investigate greater insight regarding the cellular functions of AHSA1 in LUAD. Co-immunoprecipitation and WB experiments were employed to explore potential mechanisms through which AHSA1 may regulate LUAD ***:the knock-down of AHSA1 impaired cell proliferation, apoptotic evasion, epithelial to mesenchymal transition(EMT) capacity and EGFR-TKI resistance. AHSA1 activated HSP90stabilizes TGFB1, which binds to the promoter of IFI6. IFI6 subsequently maintains the integrity of mitochondrial membranes through downregulating expression of BAX. Furthermore, elevated TGFB1 can also promote the EMT process through the classical TGFB1-SMAD3 pathway and enhance EGFR-TKI *** : Our research has unveiled that AHSA1 assumes a central and oncogenic role in EGFR-mutated LUAD through its influence on downstream HSP90/TGFB1/IFI6 axis. Targeting AHSA1 alleviates the progression of EGFR-mutant lung adenocarcinoma and EGFR-TKI resistance, and brings potential clinical application value.
暂无评论